...total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid eye disease trial. Harbour BioMed...

...to advance therapies for genetic diseases. Promising programs may become additional BridgeBio affiliate companies.AbbVie in-licenses Harbour BioMed’s...

...HK$12.38 in its IPO. The deal gave the oncology and immunology antibody company, also known as Harbour BioMed...

...Plus: Harbour BioMed files to raise up to $230.4M in HK IPO By Virginia Li, Associate Editor ...
...in October to list on NASDAQ, withdrew its application on Nov. 13, citing market conditions.Meanwhile, Harbour BioMed...

...models.Few others have disclosed programs targeting CCR8. Harbour BioMed...

...after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics Co. Ltd. and Harbour BioMed...

...of multiple COVID-19 mAb deals and a $75 million series B+ round closed in March, Harbour BioMed...
...well as Cambridge, Mass., has now raised more than $300 million to date. Virginia Li, Associate Editor Harbour BioMed...

...when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd., Harbour BioMed...

...to general partner from partner and Sarah Bhagat to partner from principal. Antibody discovery company Harbour BioMed...

...in Cambridge, Mass., Rotterdam, Suzhou and Shanghai, has raised over $200 million to date (see “Harbour BioMed...